Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2014
Event: Regulation FD Disclosure regarding positive interim data from a clinical trial.
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change disclosed is the announcement of positive interim data from the ongoing Phase I/II trial of the Company's drug candidate, Actimab-A. The trial focuses on older patients with newly diagnosed Acute Myeloid Leukemia.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (attached as Exhibit 99.1) detailing the positive interim data.
Regulatory Note: In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 is deemed "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934. It is not deemed an admission as to the materiality of the information solely to satisfy Regulation FD requirements.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific details on the positive interim data.
- Verify the specific patient population and endpoints of the Phase I/II trial for Actimab-A.
- Check subsequent filings for any updates on the trial's progression or regulatory status.
- Confirm the Company's cash position and runway in the most recent 10-Q or 10-K, as this 8-K contains no financial data.